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Abstract: The number of breast cancer survivors has increased as a result of rising incidence and
increased survival. Research has revealed significant urban–rural variation in clinical aspects of breast
cancer but evidence in the area of survivorship is limited. We aimed to investigate whether quality of
life (QoL) and treatment-related symptoms vary between urban and rural breast cancer survivors
prescribed endocrine therapy. Women with a diagnosis of stages I–III breast cancer prescribed
endocrine therapy were identified from the National Cancer Registry Ireland and invited to complete
a postal survey (N = 1606; response rate = 66%). A composite measure of urban–rural classification
was created using settlement size, population density and proximity to treatment hospital. QoL
was measured using the Functional Assessment of Cancer Therapy (FACT-G) and an endocrine
subscale. The association between urban–rural residence/status and QoL and endocrine symptoms
was assessed using linear regression with adjustment for socio-demographic and clinical covariates.
In multivariable analysis, rural survivors had a statistically significant higher overall QoL (β = 3.81,
standard error (SE) 1.30, p < 0.01), emotional QoL (β = 0.70, SE 0.21, p < 0.01) and experienced a lower
symptom burden (β = 1.76, SE 0.65, p < 0.01) than urban survivors. QoL in breast cancer survivors
is not simply about proximity and access to healthcare services but may include individual and
community level psychosocial factors.
Keywords: urban; rural; quality of life; breast cancer; survivorship; endocrine therapy
1. Introduction
More than 5 million women worldwide are living with breast cancer, almost half of whom reside
in developed countries [1]. Each year in Ireland, approximately 2600 women are diagnosed with breast
cancer and 660 women die from the disease. One in 10 women in Ireland will get breast cancer at
some stage in their lives [2]. In recent years, with earlier diagnosis and better treatment options, breast
cancer survival has increased steadily in most developed countries; it is now estimated to be 82% at
5 years [3,4]. After completing surgery and any chemotherapy or radiotherapy, the overwhelming
majority of breast cancer patients do not have progressive or terminal disease [5]. They thus transition
from a being a breast cancer patient to becoming a breast cancer survivor [6].
A critical part of the transition to survivorship care, for women with estrogen receptor positive
(ER+) breast cancer, is the use of endocrine therapy. Five to ten years of adjuvant endocrine therapy is
recommended to reduce the risks of recurrence and mortality in women with ER+ early breast cancer [7].
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Previous research indicates that almost 75% of breast cancers are hormone receptor-positive [8].
Endocrine therapies are known for their adverse effects, which include reduced cognitive function,
hot flashes, painful joints and vaginal dryness; these can have a negative impact on quality of life
(QoL), adherence to endocrine therapy and, consequently survival [9–11]. Hence, despite significant
therapeutic advances and improvements in survival at the population-level, some breast cancer
survivors experience considerable physical and psychosocial dysfunction and reduced QoL [12].
The past decade has seen major growth in research investigating the diverse experiences, complex
needs and QoL of breast cancer survivors [13]. However, there are a number of gaps in the knowledge
base. For example, in relation to those on endocrine therapy, it is unclear why some survivors
experience few adverse effects from their therapy, while others with similar disease and treatment
may have many. More generally, it is likely that the characteristics of the communities in which breast
cancer survivors live can have an effect on their survivorship outcomes; women who live in rural
and urban areas may have different supportive care needs (because of differences in availability of
services for example) and this may translate into differences in QoL. Research has revealed evidence of
significant disparities in clinical aspects of breast cancer by area of residence with more advanced stage
at diagnosis, lower treatment utilisation, poorer survival and higher mortality in women resident in
rural areas [14–16]. However, evidence in the area of breast cancer survivorship is limited and findings
are inconsistent.
A small US study (N = 46) found that, one month post-chemotherapy, breast cancer survivors
resident in more rural areas reported lower overall QoL, lower functional well-being and more breast
cancer specific symptoms, than urban dwellers [17]. Similarly, in Europe, a large study in Germany
(N = 1927) found that survivors in rural areas had worse QoL [15]. In contrast, in Poland, those who
were resident in rural areas rated their social QoL higher than those in urban areas [18,19]. Meanwhile,
in Australia a study of 600 survivors one year after breast cancer diagnosis, found that age-adjusted
QoL among urban and rural survivors was similar [12]. None of these studies focused on survivors on
endocrine therapy.
There is a need to further investigate associations between urban–rural residence and aspects of
QoL in different settings where concepts of urbanisation and rurality may have different meanings
and implications. Such research would help to establish whether there are disparities in survivors’
supportive care needs and, if so, enable the appropriate and effective development and delivery of
health and supportive care services to all sectors of the breast cancer survivor population [20]. The
aim of this study, therefore, was to investigate whether QoL and treatment-related symptoms vary
between urban and rural survivors of breast cancer prescribed adjuvant endocrine therapy.
2. Methods
2.1. Study Population
Women with breast cancer were identified in August 2015 from the National Cancer Registry
Ireland (NCRI) database [21]. The NCRI records detailed demographic and clinical information for all
incident cancers diagnosed in the population usually resident in Ireland. Completeness of registration
is high, especially for breast cancer [22]. Eligibility criteria were (i) aged ≥18 years; (ii) had a diagnosis
of stages I–III, estrogen (ER) or progesterone (PR) receptor positive breast cancer between 1 July 2009
and 30 June 2014; (iii) received tumour directed surgery; (iv) were prescribed adjuvant endocrine
therapy (selective estrogen receptor modulator, SERM; aromatase inhibitor, AI) within one year of
their breast cancer diagnosis and for no more than 5 years before the study start date; and (v) were
alive. Women were excluded if they had previously been diagnosed with another invasive cancer
other than non-melanoma skin cancer.
Each potentially eligible woman’s details were screened by their General Practitioner (GP) to
confirm that there was no medical or other reason that would make it inappropriate to contact them
about the study. The remaining eligible women were invited, by post, to take part in the study and
Int. J. Environ. Res. Public Health 2017, 14, 394 3 of 13
self-complete a questionnaire [21]. Ethical approval was granted by the Irish College of General
Practitioners. All participants provided informed consent to participate in the study.
2.2. Outcome Measures QoL
QoL was measured using the Functional Assessment of Cancer Therapy (FACT-G) [23]. FACT-G
is a well validated multi-dimensional self-report questionnaire that assesses four primary domains
of QoL; physical (PWB: seven items), social and family (SFWB: seven items), emotional (EWB: six
items) and functional well-being (FWB: seven items). It asks about the past week and uses 5-point
Likert-type response categories ranging from 0 = ‘not at all’ to 5 = ‘very much’ [23]. It has good
psychometric properties, discriminates well between clinically distinct groups, and is responsive to
change [24,25]. It is also validated for use in different countries and with rural populations [26,27]. The
individual domain scores were calculated using the pre-defined scoring programme; as recommended,
where participants had to have answered at least half of the questions in a domain to be included
in the subscale score for that domain [28]. A 19-item endocrine subscale (ES) was also included
which measures endocrine symptoms and adverse effects of endocrine therapy [29,30]. The endocrine
subscale uses the same 5-point Likert-type response categories and scoring method as the FACT-G. The
endocrine subscale score is added to the FACT-G to give an overall QoL score (FACT-ES) for women
with breast cancer prescribed endocrine therapy [29,30]. A higher overall QoL score (FACT-ES) and
higher individual domain scores and endocrine subscale scores indicate higher/better QoL [28].
2.3. Urban–Rural Measure
A number of health-related studies have indicated that the use of a single indicator to identify
urban–rural areas does not adequately capture the range of urban and rural area types and suggest
the use of multiple measures to reduce the probability of misclassification [31]. A composite measure
of urban–rural classification was created using three indicators; settlement size, population density
and proximity to treatment hospital. These indicators have all been used previously as indicators
in urban–rural classifications and take into account the range of settlement and area types in
Ireland [31,32]. The use of a composite measure gives a more complete measure of urbanicity and
rurality, rather than privileging one type of measurement over another [32]. Participants who were
classified as rural for at least two of the three component indicators were classified as rural for the
composite measure [32].
Settlement size was measured as the self-reported area size where the participant was living
at the time of the questionnaire completion. In line with the Irish Census Office definition of rural,
participants who responded “Village” and “Open country” were classified as rural and those who
responded “Dublin city/county”, “City other than Dublin” and “Town (1500+)” were classified as
urban [33]. Population density of the area the participant lived at the time of questionnaire completion
was classified as rural if “<1 person per hectare” and urban if “≥1 person per hectare” based on
2006 census small-area populations. This urban–rural classification has been used in Ireland in
previous studies [32,34]. Proximity to treatment hospital was measured as the distance from the
participant’s residence at diagnosis to the main treatment hospital. The main treatment hospital was
defined as where the participant had their breast cancer surgery or other treatments/procedures
(e.g., chemotherapy, radiotherapy), or both and was obtained from the NCRI database. Participants
were grouped into three approximately equal-sized tertiles based on this distance. The last tertile of
distance from the treatment hospital (≥60 km; approximately 75 min travel time) was classified as
rural, while the two closest tertiles (<60 km) were classified as urban [31,32].
2.4. Covariates
Socio-demographic and clinical variables identified as predictors of QoL in the literature were
included as covariates [35]. Socio-demographic covariates included women’s self-reported age,
relationship status, education level, occupational status, socioeconomic status and smoking status.
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Women who reported being married, cohabiting or in a long-term relationship with a partner were
classified as being in a relationship. Socioeconomic status was measured using a census-based
deprivation score (five levels ranging from least to most deprived) [36]. Women were also asked
whether they had a medical card at the time of their breast cancer diagnosis. A medical card
provides individuals with free or substantially-subsidised health care and prescription medications
and eligibility is means-tested; medical card status is therefore considered a proxy for socioeconomic
status [37]. Smoking status at diagnosis was obtained from the NCRI database. Clinical information
available from the NCRI database included receipt of chemotherapy and radiotherapy. Women were
classified into four treatment groups: (i) chemotherapy only; (ii) radiotherapy only; (iii) chemotherapy
and radiotherapy and; (iv) no chemotherapy or radiotherapy.
2.5. Statistical Analysis
Descriptive statistics including means (standard deviation, SD), medians (inter-quartile range,
IQR) and proportions, were calculated for all socio-demographic, clinical, QoL and endocrine
symptoms (FACT-ES) variables. Urban–rural differences between these variables were examined
using chi-square tests for categorical variables and non-parametric Wilcoxon–Mann–Whitney tests for
continuous variables (participants’ age, QoL and endocrine symptoms).
The association between the composite urban–rural variable and overall QoL (FACT-ES) and
for each individual domain and endocrine symptoms were assessed using linear regression analysis
with adjustment for the socio-demographic and clinical covariates described above and using robust
standard errors. The use of robust standard errors (sandwich estimator) controls for mild violation of
the homoskedasticity and normality distribution assumption in linear regression [38]. The data was
analysed using Stata Version 14.0 (StataCorp, College Station, TX, USA).
3. Results
3.1. Study Population
Of the 1606 (response rate = 66%) breast cancer survivors who completed the questionnaire,
1568 (98%) had complete urban–rural data and were included in the analysis. The mean age of
these women was 60 years (SD = 10.2, range = 34–86 years); the majority were married or in a
long-term relationship (N = 1175, 73.4%) and almost half (720, 45.3%) had completed third level
(degree) or post-graduate education. There were no significant differences in age between responders
and non-responders but the proportion of women married was significantly higher in the respondent
group (73%) than in the non-respondent group (61%, p value < 0.01).
In total, 870 (55.5%) participants were classified as urban and 698 (44.5%) were classified as rural.
Table 1 presents the socio-demographic and clinical characteristics of the survivors by urban and
rural residence. A statistically significant higher proportion of rural participants were married or in
a long-term relationship compared with urban participants (p < 0.01). A higher proportion of urban
participants were resident in more affluent areas (p < 0.01) and were former smokers compared to rural
participants (p < 0.05). There were no statistically significant clinical differences between rural and
urban participants (Table 1).
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Table 1. Socio-demographic and clinical characteristics of urban and rural survivors of stages I–III
breast cancer prescribed endocrine therapy.
Urban (N = 870) Rural (N = 698) p-Value a
N (%) N (%)
Socio-demographics
Age—mean (SD) 60.4 (10.3) 59.7 (10.1) p = 0.17
Marital status
Not in a relationship 266 (30.7) 152 (21.8) p < 0.01 *
Married/long-term relationship b 599 (69.3) 545 (78.2)
Education
Primary 110 (12.8) 95 (13.7) p = 0.74
Secondary 362 (42.1) 279 (40.3)
Third level or post-graduate 388 (45.1) 318 (46.0)
Occupational status
Employed
(employee/self-employed) 313 (36.4) 271 (39.0) p = 0.08
Looking after family/home 168 (19.6) 165 (23.7)
Retired from employment 248 (28.9) 169 (24.3)
Unable to work (sickness/disability) 86 (10.0) 63 (9.1)
Other c 44 (5.1) 27 (3.9)
Deprivation
1 (least deprived) 205 (23.6) 62 (8.9) p < 0.01 *
2 196 (22.5) 152 (21.8)
3 143 (16.4) 197 (28.2)
4 157 (18.1) 180 (25.8)
5 (most deprived) 169 (19.4) 107 (15.3)
Smoking status at diagnosis
Current 124 (14.5) 100 (14.6) p < 0.05*
Former 145 (16.9) 78 (11.3)
Never 460 (53.7) 400 (58.2)
Unknown 128 (14.9) 109 (15.9)
Medical card d
Yes 276 (32.0) 288 (32.7) p = 0.09
No 587 (68.0) 469 (67.3)
Clinical
Chemotherapy and/or Radiotherapy
Chemotherapy only 82 (9.4) 66 (9.5) p = 0.25
Radiotherapy only 330 (37.9) 252 (36.1)
Chemotherapy and radiotherapy 372 (42.8) 327 (46.9)
No chemotherapy or radiotherapy 86 (9.9) 53 (7.6)
* p < 0.05; a Wilcoxon–Mann–Whitney test; b Long-term relationship—cohabiting or in a stable relationship;
c Other—unemployed, student (undertaking training/education); d Medical card provides individuals with free
or substantially-subsidised health care and prescription medications and eligibility is means-tested, medical card
status is therefore considered a proxy for socioeconomic status; SD: Standard deviation.
3.2. QoL and Endocrine Symptoms
Table 2 presents summary statistics for overall QoL (FACT-ES), the individual QoL domains
and the endocrine subscale by urban–rural residence. In these unadjusted analyses, breast cancer
survivors living in rural areas reported better overall (Wilcoxon–Mann–Whitney z-score = −2.69,
p < 0.01), physical (z-score = −2.10, p < 0.05), emotional (z-score = −3.57, p < 0.01) and functional
(z-score = −3.17, p < 0.01) QoL than women living in urban areas. Social domain scores and endocrine
symptoms did not significantly differ by urban–rural residence.
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Table 2. Median (with IQRs) for overall QoL domain scores and endocrine symptoms for urban and
rural survivors of stages I–III breast cancer.
All Participants Urban (N = 870) Rural (N = 698) Urban–RuralComparison
QoL Median IQR N Median IQR N Median IQR z-Score p-Value
Overall QoL (FACT-ES) 124 106–140 804 123 104–138 646 126 107–143 −2.69 <0.01 *
Physical domain 24 21–27 845 24 20–27 681 25 21–27 −2.10 <0.05 *
Social domain 22 17–26 844 22 17–26 677 22 17–26 −0.56 0.58
Emotional domain 20 17–23 838 20 17–22 671 20 18–23 −3.57 <0.01 *
Functional domain 21 17–26 843 21 17–25 672 22 18–26 −3.17 <0.01 *
Endocrine symptoms 40 29–48 845 39 29–47 681 41 30–49 −1.90 0.06
IQR: inter-quartile range; QoL: quality of life; FACT-ES: Functional Assessment of Cancer Therapy, endocrine
subscale; * Wilcoxon–Mann–Whitney test: A higher overall QoL (FACT-ES), individual domain score or endocrine
symptom score indicates a higher/better QoL (or lower symptom burden).
3.3. Multivariable Analysis: Associations between Urban–Rural Variation and QoL and Endocrine Symptoms
Table 3 presents the association between the FACT-ES, the individual QoL domains and the
endocrine subscale and urban–rural residence, following adjustment for socio-demographic and
clinical covariates. In these multivariable analyses, breast cancer survivors living in rural areas had a
statistically significant higher overall QoL (β = 3.81, standard error (SE) 1.30, p < 0.01) and emotional
QoL (β = 0.70, SE 0.21, p < 0.01) and a lower endocrine symptom burden (β = 1.76, SE 0.65, p < 0.01)
than urban survivors. Physical and functional QoL were no longer significantly associated with living
in rural areas.
In terms of socio-demographic and clinical covariates, increasing age (β = 0.59, SE 0.09, p < 0.01),
having never smoked (β = 4.82, SE 2.00, p < 0.05) and receipt of radiotherapy only (without
chemotherapy) (β = 4.96, SE 2.53, p < 0.05) were associated with a significantly higher overall QoL.
Inability to work due to sickness or disability (β =−22.44, SE 2.66, p < 0.01) was significantly associated
with a lower overall QoL (Table 3). Women who were married or in a long-term relationship had a
significantly higher social (β = 1.59, SE 0.42, p < 0.01) and functional QoL (β = 1.06, SE 0.39, p < 0.01)
but experienced a greater endocrine symptom burden (β = −2.73, SE 0.76 p < 0.01) (Table 3).
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Table 3. Unadjusted and adjusted coefficients (SE) for FACT-ES, individual domains and endocrine symptoms by urban–rural, socio-demographic and clinical
factors a.
Overall QoL (FACT-ES) Physical Social Emotional Functional Endocrine Symptoms
Unadjusted β
(SE)
Adjusted β
(SE)
Unadjusted
β (SE)
Adjusted β
(SE)
Unadjusted
β (SE)
Adjusted β
(SE)
Unadjusted
β (SE)
Adjusted β
(SE)
Unadjusted
β (SE)
Adjusted β
(SE)
Unadjusted
β (SE)
Adjusted β
(SE)
Urban–rural
Rural (vs. urban) 3.85 (1.36) * 3.81 (1.30) * 0.48 (0.25) * 0.36 (0.24) 0.25 (0.33) 0.11 (0.35) 0.76 (0.20) * 0.70 (0.21) * 0.81 (0.32) * 0.53 (0.32) 1.37 (0.70) * 1.76 (0.65) *
Socio-demographic
Age (at survey completion- continuous) 0.70 (0.06) 0.59 (0.09) * 0.07 (0.01) * 0.06 (0.02) * 0.05 (0.02) * 0.06 (0.02) * 0.07 (0.01) * 0.05 (0.01) * 0.01 (0.02) 0.03 (0.02) 0.49 (0.03) * 0.40 (0.05) *
Marital status (vs. no relationship) b
Married/long-term relationship −1.61 (1.54) 0.10 (1.53) −0.17 (0.27) −0.11 (0.28) 1.36 (0.39) * 1.59 (0.42) * −0.22 (0.23) −0.06 (0.24) 1.30 (0.37) * 1.06 (0.39) * −4.73 (0.77) * −2.73 (0.76) *
Education (vs. primary)
Secondary −3.79 (2.16) −0.36 (2.23) 0.18 (0.37) 0.24 (0.41) −0.80 (0.53) −0.61 (0.57) −0.26 (0.33) 0.05 (0.36) 0.56 (0.54) 0.04 (0.57) −2.95 (1.09) * −0.12 (1.11)
Third level or post-graduate −6.07 (2.13) * −1.55 (2.44) −0.66 (0.37) −0.60 (0.46) −0.83 (0.51) −0.47 (0.60) −0.56 (0.32) −0.11 (0.38) 1.16 (0.52) * 0.32 (0.60) −4.89 (1.08) * −1.00 (1.23)
Occupational status (vs. employed)
Looking after family/home 5.84 (1.70) * 1.16 (1.88) 0.71 (0.29) * 0.09 (0.33) 0.57 (0.44) 0.02 (0.49) 0.46 (0.26) 0.02 (0.30) −0.05 (0.39) 0.11 (0.41) 4.55 (0.88) * 1.09 (0.97)
Retired from employment 9.71 (1.60) * 0.99 (1.99) 0.64 (0.27) * −0.23 (0.35) 0.72 (0.41) 0.02 (0.55) 1.09 (0.24) * 0.26 (0.32) −0.46 (0.39) −0.23 (0.49) 7.57 (0.83) * 0.52 (1.01)
Unable to work (sickness or disability) −23.24 (2.24) * −22.44 (2.66) * −5.04 (0.54) −4.97 (0.55) * −1.09 (0.57) −1.08 (0.61) −2.32 (0.42) −2.17 (0.43) * −6.16 (0.52) * −5.43 (0.57) * −8.44 (1.17) * −8.88 (1.31) *
Other c −6.48 (3.11) * −6.34 (3.41) −0.92 (0.61) −0.94 (0.64) 0.96 (0.95) −1.26 (0.96) −1.18 (0.56) * −1.20 (0.54) * −2.34 (0.82) * −1.71 (0.87) * −1.24 (1.59) −1.11 (1.74)
Deprivation (vs. least deprived)
2 1.84 (2.16) 0.70 (2.04) 0.79 (0.41) 0.62 (0.38) −0.52 (0.53) −0.53 (0.53) 0.05 (0.34) 0.01 (0.33) 0.32 (0.51) 0.45 (0.49) 1.51 (1.08) 0.69 (1.02)
3 −0.17 (2.18) −0.93 (2.16) 0.31 (0.42) 0.25 (0.40) −0.39 (0.53) −0.34 (0.55) 0.31 (0.35) 0.25 (0.34) −0.01 (0.53) 0.24 (0.52) −0.15 (1.13) −0.82 (1.07)
4 0.60 (2.19) −0.37 (2.12) 0.44 (0.41) 0.31 (0.40) −0.26 (0.53) −0.29 (0.56) 0.16 (0.34) 0.07 (0.34) 0.38 (0.51) 0.71 (0.51) 0.41 (1.12) −0.52 (1.07)
5 −1.10 (2.29) −0.34 (2.26) −0.29 (0.45) −0.21 (0.45) 0.12 (0.55) 0.38 (0.58) −0.04 (0.37) 0.16 (0.37) −0.33 (0.55) 0.50 (0.55) −0.19 (1.20) −0.90 (1.14)
Smoking status (vs. current)
Former 4.72 (2.96) 1.26 (2.59) 1.02 (0.49) * 0.55 (0.48) 0.15 (0.63) −0.21 (0.65) 0.40 (0.42) 0.02 (0.42) 0.77 (0.58) 0.20 (0.58) 5.67 (1.12) * 3.08 (1.00) *
Never 9.60 (1.96) * 4.82 (2.00) * 1.42 (0.40) * 0.71 (0.37) 0.77 (0.50) 0.48 (0.52) 1.09 (0.34) * 0.63 (0.34) 1.35 (0.47) * 0.38 (0.48) 2.99 (1.37) * 1.26 (1.29)
Unknown 7.50 (2.46) * 3.99 (2.38) 1.19 (0.48) * 0.74 (0.45) 0.19 (0.64) −0.03 (0.66) 1.05 (0.41) * 0.71 (0.41) 0.90 (0.59) 0.34 (0.58) 4.80 (1.34) * 2.62 (1.18)
Medical card (vs. Yes)
No d 0.47 (1.45) 2.50 (1.58) 0.43 (0.27) 0.45 (0.30) 0.14 (0.36) 0.12 (0.42) 0.31 (0.32) 0.56 (0.26) * 1.92 (0.35) * 1.34 (0.39) * −2.64 (0.74) * −0.04 (0.79)
Clinical
Chemotherapy and/or radiotherapy (vs. none)
Chemotherapy only −5.10 (3.06) 0.33 (3.24) −1.08 (0.55) * −0.30 (0.58) 0.74 (0.75) 1.13 (0.83) −0.84 (0.46) −0.39 (0.52) 0.28 (0.71) 0.98 (0.78) −3.06 (1.58) * 0.05 (1.57)
Radiotherapy only 5.20 (2.43) * 4.96 (2.53) * 0.48 (0.44) 0.48 (0.43) 1.58 (0.60) * 1.49 (0.69) * 0.78 (0.37) * 0.79 (0.41) 1.41 (0.57) * 1.53 (0.66) * 1.20 (1.26) 0.97 (1.22)
Chemotherapy and radiotherapy −0.83 (2.38) 3.88 (2.57) −0.32 (0.43) 0.37 (0.45) 1.51 (0.59) * 1.67 (0.68) * −0.41 (0.36) 0.04 (0.42) 0.66 (0.56) 0.97 (0.64) −2.26 (1.24) 1.15 (1.26)
β: coefficient, SE: standard error; * p < 0.05; a Multicollinearity was assessed by calculating the variance inflation factor (VIF) for each independent variable (VIF < 10; mean VIF = 1.72);
b Long-term relationship—cohabiting or in a stable relationship; c Other—unemployed, student (undertaking training/education); d Medical card provides individuals with free or
substantially-subsidised health care and prescription medications and eligibility is means-tested, medical card status is therefore considered a proxy for socioeconomic status.
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4. Discussion
In this, the first study of urban–rural variations in QoL in survivors of stages I–III breast cancer
prescribed endocrine therapy, those living in rural areas had significantly higher emotional and overall
QoL and experienced a lower endocrine symptom burden than those living in urban areas, after
controlling for socio-demographic and clinical variables. The difference in QoL between rural and
urban breast cancer survivors was approximately four points and, therefore, would be considered
clinically significant. The minimal important difference (MID) for interpreting group differences
or changes in QoL over time for FACT breast cancer scales is estimated to be in the range of
3–8 points [39,40].
These intriguing findings are inconsistent with previous research [41]. The majority of studies
have reported lower QoL in cancer survivors in rural settings and have found that rural patients
have higher needs in the domains of physical/daily living and psychological morbidity and are more
likely to experience distress, high levels of depression and hopelessness/helplessness, as well as
stigmatisation [17,41]. However, the findings are consistent with a study of QoL in urban and rural
settings in head and neck cancer survivors in Ireland. In that study, rural survivors reported higher
physical and emotional QoL than urban survivors [32]. The findings are also consistent with a study of
the general population in Ireland which found better psychosocial well-being in rural populations [42].
Rural and urban life is not homogenous across countries and this may help explain differences
between countries. Traditionally, rural living is often perceived as advantageous in terms of offering
greater space and a slower pace of life than urban living but disadvantageous in terms of poorer access
to health services and healthcare professionals [31,43]. Our findings suggest that access to services and
professionals may not be a major driver of survivorship outcomes, at least in Ireland. Clearly, many
different regional, community and individual patient factors may influence QoL for breast cancer
survivors [17]. Understanding the reasons for greater well-being in breast cancer survivors in rural
areas in Ireland requires identifying the major influences on QoL in women resident in different areas
in the early stages following breast cancer treatment completion.
In terms of explaining our findings, it is possible that urban and rural woman differ in the ways in
which they cope with endocrine side-effects or in the impact of their coping strategies on their QoL [44].
The finding of higher emotional well-being in rural women may be related to coping, specifically an
increased ability to cope with the stress and severity of their breast cancer and its treatment. A study
of psychological adjustment in rural and urban breast cancer survivors found that a belief that their
decisions and life are controlled by environmental factors which they cannot influence (external locus
of control) had a negative impact on the psychological well-being of urban breast cancer patients,
but this was not true for rural patients [45]. Studies have indicated that rural women with breast
cancer tend to adopt a “positive attitude” as a coping strategy in response to their cancer [46]. Coping
strategies such as “active coping” and “positive reinterpretation” have been found to be negatively
associated with depression in rural breast cancer patients undergoing radiotherapy but not in their
urban counterparts [44]. There is also evidence that people living in rural areas tend to be more stoic
and resilient about their health and differ in their expectations and demands of the health services
than their urban counterparts [47,48].
Social support has been shown to be a strong positive predictor of QoL in breast cancer
survivors [35]. Women in a relationship experienced a greater endocrine treatment burden but had
significantly higher social and functional QoL domain scores than their single counterparts. Previous
research has found that socially isolated women have a higher risk of mortality after a breast cancer
diagnosis and this is likely due to a lack of beneficial caregiving from friends, relatives and adult
children [49]. Previous research has also indicated that among breast cancer survivors, the most
important source of support is often not the women’s spouses but other members of their social
network [49]. There is evidence, in Ireland, that urban dwellers are more socially isolated compared to
rural dwellers [50]. In a national Irish lifestyle survey, those living in rural areas reported a greater
ability to get both practical help and personal support from neighbours than those living in urban
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areas [51]. A study of head and neck cancer survivors in Ireland also found that having problems
getting support from neighbours was associated with having unmet needs [52].
Geographic distance to professional clinical and psychological support has been cited as a reason
for poorer QoL in rural cancer populations. In Ireland, 7% of rural patients live within walking
distance of their General Practitioner (GP) compared to 89% of urban dwellers and the longest
average travel times occur in the most deprived rural areas [53]. However other characteristics of
rural communities may actually be of benefit to women coping with cancer including their local
community services and their social networks [17]. It is feasible that as breast cancer survivorship
care has become predominantly outpatient based care, breast cancer survivors in the rural setting may
have developed local social networks, with network members providing informal emotional support
previously provided by healthcare professionals [49]. Informal supports in rural communities have
been reported to be highly effective in assisting people through a health-related crisis [54].
In terms of socio-demographic and clinical covariates, increasing age, having never smoked and
receipt of radiotherapy only were associated with greater well-being, while inability to work (due
to sickness/ill-health/unemployment) had a negative influence on QoL. These factors have all been
identified previously as predictors of QoL in breast cancer survivors [35]. Receipt of chemotherapy has
been shown to be a statistically significant predictor of a poor current quality of life [55]. Increasing
age was also associated with experiencing less endocrine symptoms. Adverse effects of endocrine
therapy are more common in older woman but studies have reported no impact on their QoL scores,
possibly due to older women being less likely to report complaints than younger women [30,56].
This is the first study of urban–rural variations in QoL among breast cancer survivors prescribed
endocrine therapy. The sampling frame was a high-quality population-based cancer registry. Although
the response rate was 66%, we cannot exclude the possibility that respondents had better (or worse)
QoL than non-respondents but, unless response was differential by area of residence, this should
not affect the urban–rural comparisons. The cross-sectional design means we not know whether
temporal trajectories of QoL vary between urban and rural survivors. While we adjusted for a range
of socio-demographic and clinical covariates, we lacked information on other potentially important
influences on QoL (such as coping styles and social support). We also did not consider the type of
endocrine therapy women were prescribed and whether or not they were adherent to their therapy.
Previous research has found that many women do not take their endocrine therapy as recommended;
rates of non-adherence range between 38% to 60% in routine clinical settings at 5 years [57,58].
Given our findings, a more thorough investigation of the psychosocial influences on QoL is
needed in order to understand the differences in QoL in breast cancer survivors in urban and rural
settings. This includes an exploration of individual coping skills, self-efficacy and resilience in urban
and rural breast cancer survivors who are prescribed endocrine therapy. Future research should also
document and evaluate both the formal and informal support services available and accessed by
urban and rural breast cancer survivors, as well as the quality and type of support (e.g., instrumental,
emotional).
5. Conclusions
In conclusion, this large study of breast cancer survivors prescribed endocrine therapy found
that those living in rural areas had significantly higher emotional and overall QoL and experienced
a lower endocrine symptom burden than those living in urban areas. These findings suggest that
QoL in breast cancer survivors is not simply about access and proximity to health care services and
professionals. In order to develop interventions and services tailored to the specific needs of these two
populations, future research needs to identify both the individual and community level psychosocial
factors influencing QoL in breast cancer survivors in rural settings and whether these factors can be
transferred to an urban setting.
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